| Model Number |
FX803T |
| Medical Device Problem Code |
Mechanical Problem (1384)
|
| Health Effect - Clinical Code |
Hydrocephalus (3272)
|
| Date of Event |
10/21/2021
|
|
Type of Reportable Event
|
Serious Injury
|
|
Event or Problem Description
|
|
It was reported that a m.Blue 15 valve (part # fx803t) was implanted during a procedure performed on (b)(6) 2019.According to the complainant, the shunt system was believed to be difficult to adjust.The patient underwent a revision procedure on (b)(6) 2021.The complaint device was returned to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.Age: (b)(6), height: 163 centimeters (cm), weight: (b)(6), gender: male.
|
| |
|
Additional Manufacturer Narrative
|
|
Manufacturing and quality control data.The m.Blue® was manufactured by a qualified employee in june 2019.Deviations during assembly did not occur.The valve was sterilized by miethke and released for shipment after final inspection.The m.Blue® has a fixed pressure of 15 cmh2o in the horizontal position and a normal pressure range of 0 to 40 cmh2o in the vertical position.The valve was inspected as article (b)(4).All parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specifications.Visual inspection: no significant deformations or damage of the valve were detected during the visual inspection.Permeability test: a permeability test has shown that the valve is permeable.Adjustment test: the m.Blue® valve was tested and is adjustable to all specified pressures.Braking force and brake function test: the brake functionality test has shown that the brake function is fully operational and the braking force is within the given tolerances.Internal inspection : after dismantling of the valve, minimal deposits were found in m.Blue®.Results: based on our investigation, we are unable to substantiate the clinical claim of non adjustability.At the time of our investigation the valve was inside the tolerances.However, it is possible that the deposits observed inside the valve could have caused the malfunction in the past.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hc-therapy by shunt implants.We can exclude a defect at the time of release.The valve met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required from our point of view.
|
| |
|
Search Alerts/Recalls
|